Since late 2016, Chinese and American researchers have engaged in cutting-edge clinical research that has confirmed the safety and efficacy of reprogramming the human immune response to eradicate lung cancer. Using guided molecular editing enzymes, PD-1 – the protein that prevents the human immune system from using its full power to fight off terminal cancers – can be disabled.

Normally, cancer cells take advantage of the role PD-1 plays, using it as an opportunity to spread uncontrollably throughout the body.

Once freed of PD-1’s limitations, the patient can receive what they need most – infusions of new and highly-optimized T-cells that act as the front-line offensive needed to eliminate the presence of cancer entirely.

Trials are now open for 50 individuals seeking a cure and non-remission for non-small cell lung cancer  Though the trial is open to all individuals experiencing lung cancer of any form, patients who are experiencing non-small cell lung cancer, and who have a failed history of treatment through traditional methods such as chemotherapy, are preferred.